JLL to buy more CMOs; Regeneron nabs an approval in Japan for Eylea; Soros buys up Teva shares;

@FiercePharma: Thursday's best-read special report: Top 10 Patent Losses of 2014. Report | Follow @FiercePharma

@EricPFierce: Pfizer says it will close a Puerto Rico plant days after Merck says the same thing. Story | Follow @EricPFierce

@CarlyHFierce: Biogen Idec's MS pill Tecfidera wins 10 years' protection in EU. Analysts expect 36% of $4.5B in 2018 sales to come from non-U.S. More | Follow @CarlyHFierce

> Paul Levy, cofounder of JLL Partners, says he expects the company to buy more contract manufacturers as a follow-up to its $2.6 billion deal to buy the pharmaceutical unit of Dutch-based Royal DSM and combine it with CMO Patheon. Story

> Regeneron Pharmaceuticals ($REGN) said Japan has approved Eylea for the treatment of macular edema following central retinal vein occlusion (CRVO). Story

> GlaxoSmithKline ($GSK) has announced a plant expansion in Scotland that will add 25 jobs when complete. Story

> In more bad news for Amarin ($AMRN), its said the FDA will not consider its appeal of its regulatory decision to revoke an agreement related to the trial of Vascepa. Story

> Soros Fund Management, the investment vehicle for billionaire George Soros, has upped its stake in Teva Pharmaceutical Industries ($TEVA), which has been floundering in the wake of letting its CEO go. Story  

> India's Biocon has gotten approval from the Indian drug regulator to produce a biosimilar version of Roche's ($RHHBY) blockbuster Herceptin. Story

Medical Device News

@FierceMedDev: Myriad partners up with BioMarin for cancer diagnostics. Yesterday's story | Follow @FierceMedDev

@MarkHFierce: OraSure dumped Roche in favor of Thermo Fisher for a drug testing Dx development deal. Strategic, not fickle. Yesterday's story | Follow @MarkHFierce

@MichaelGFierce: FDA allows pivotal trial of Actinium's armed-antibody isotope delivery. More from FierceDrugDelivery | Follow @MichaelGFierce

> Covidien plans $18M Florida expansion as it cuts and reorganizes elsewhere. Story

> Cyberonics shares climb again after fruitful Q2. Article

> J&J now mulling three bids for Ortho Clinical Dx division. More

> Judge cautions that unscrupulous attorneys may exploit J&J hip settlement. Item

Biotech News

@FierceBiotech: Avalon jumpstarts first biotech in $500M GlaxoSmithKline portfolio deal. Article | Follow @FierceBiotech

@JohnCFierce: Lots of biotech startup news this month. Lots of deal flow in the pipeline. | Follow @JohnCFierce

@DamianFierce: Meet LEE011, Novartis's overnight celebrity breast cancer candidate. News | Follow @DamianFierce

@EmilyMFierce: Eli Lilly, Project A.L.S. forge preclinical drug discovery pact. Story | Follow @EmilyMFierce

> Regeneron, Sanofi hit a trio of goals in first PhIII test of rheumatoid arthritis drug. Story

> Novartis sneaks up on Pfizer with CDK4/6 cancer challenger. Article

> Food allergy startup bags $17M for oral immunotherapy. News

And Finally... Merck ($MRK), pointing to the high maternal death rate in the U.S., is bringing its Merck for Mothers, a program designed to help reduce maternal deaths tied to pregnancy that it created for developing countries, to the U.S. Release

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.